BARD1 Life Sciences inks critical deal to develop autoantibody test
BARD1 Life Sciences (ASX:BD1) has penned an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test using ProcartaPlex® technology.
BD1 is a small-cap biotech company focused on developing and commercialising non-invasive cancer diagnostics. Its proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.
This agreement defines the development of a multiplex immunoassay in kit format for the semi-quantitative detection of autoantibodies against 20 BARD1 peptides using ProcartaPlex® technology for performance on Luminex® instrumentation for BD1’s research and evaluation.
The scope of work includes the transfer of the current BARD1 assay design to Thermo Fisher for optimisation of an autoantibody assay using the ProcartaPlex® technology for BD1’s research use.
The first application of the ProcartaPlex® technology is to the BARD1-Ovarian test, which BD1 plans to develop for detection of ovarian cancer.
The custom research assay development project began on May 18 and is expected to take around nine months, with deliverables including Assay Feasibility Report, Development Report, Protocol, Standard Operating Procedures, Assay Validation Report, BARD1-autoantibody kits for research and evaluation, and transfer documentation.
If the development project is successful, the two companies will discuss potential for Thermo Fisher to supply research autoantibody kits to BD1 for its use in research studies.
BD1 CEO, Dr Leearne Hinch, said: “We are pleased to work with such an experienced partner. The development of a RUO BARD1 autoantibody assay for use on Luminex® instrumentation will be an important milestone for the company, enabling us to initiate clinical testing to evaluate the accuracy of the new multiplex BARD1-Ovarian test for early detection of ovarian cancer in early 2019.”
As always, it should be noted that BD1 is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.